Browsing Radiotherapy and Imaging by subject "NCRI CTRad Academia-Pharma Joint Working Group"

Now showing items 1-1 of 1

    • Clinical development of new drug-radiotherapy combinations. 

      Sharma, RA; Plummer, R; Stock, JK; Greenhalgh, TA; Ataman, O; Kelly, S; Clay, R; Adams, RA; Baird, RD; Billingham, L; Brown, SR; Buckland, S; Bulbeck, H; Chalmers, AJ; Clack, G; Cranston, AN; Damstrup, L; Ferraldeschi, R; Forster, MD; Golec, J; Hagan, RM; Hall, E; Hanauske, A-R; Harrington, KJ; Haswell, T; Hawkins, MA; Illidge, T; Jones, H; Kennedy, AS; McDonald, F; Melcher, T; O'Connor, JPB; Pollard, JR; Saunders, MP; Sebag-Montefiore, D; Smitt, M; Staffurth, J; Stratford, IJ; Wedge, SR; NCRI CTRad Academia-Pharma Joint Working Group (2016-10)
      In countries with the best cancer outcomes, approximately 60% of patients receive radiotherapy as part of their treatment, which is one of the most cost-effective cancer treatments. Notably, around 40% of cancer cures ...